Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNIC, INC.IMUX · Entity 6306 | Chief Medical Officer | April 24, 2026 | April 29, 2026 |
| LeonaBio, Inc.LONA · Entity 1487 | Director | June 23, 2026 | June 24, 2026 |
| Wave Life Sciences, Inc.WVE · Entity 4976 | See Remarks | July 25, 2022 | July 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNIC, INC.
Report date April 24, 2026 · Filed April 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2036-04-24 | Direct | 300,000 |
Reported balance
After 2026-04-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-24 · Grant · Acquired 300,000 · Balance 300,000 F1: The options disclosed on this Form 4 are time vested; 50 percent of the shares underlying the options awarded to the Reporting Person will vest on April 24, 2027, and 50 percent of them will vest in 24 equal monthly installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options disclosed on this Form 4 are time vested; 50 percent of the shares underlying the options awarded to the Reporting Person will vest on April 24, 2027, and 50 percent of them will vest in 24 equal monthly installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date.
LeonaBio, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22 | Direct | 28,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Wave Life Sciences, Inc.
Report date July 25, 2022 · Filed July 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2032-07-25 | Direct | 60,000 |
Reported balance
After 2022-07-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-25 · Grant · Acquired 60,000 · Balance 60,000 F1: The option vests as to 50% of the shares on July 25, 2023 and 50% on July 25, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 50% of the shares on July 25, 2023 and 50% on July 25, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 22:33 UTC | LeonaBio, Inc. LONA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001679039-26-000003 · form4-06242026_100601.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-22 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| April 24, 2026 Filed Apr 29, 2026 11:14 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 300,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001193805-26-000529 · e665406_4-panzara.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-04-24 F1 · derivative.exercise_date: The options disclosed on this Form 4 are time vested; 50 percent of the shares underlying the options awarded to the Reporting Person will vest on April 24, 2027, and 50 percent of them will vest in 24 equal monthly installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 20:59 UTC | LeonaBio, Inc. LONA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $9.54 | $0.00 |
DisclosureSEC source: 0001679039-26-000002 · form4-04132026_080418.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-04-08 F1 · derivative.exercise_date: The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 21:36 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001415889-25-015440 · form4-06032025_090615.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2035-05-29 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 30, 2026, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| May 24, 2024 Filed May 24, 2024 22:56 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001415889-24-014573 · form4-05242024_100543.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2034-05-23 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 24, 2025, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 24, 2024. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| May 19, 2023 Filed May 22, 2023 22:01 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-23-031559 · doc4.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2033-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 19, 2024, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 19, 2023. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 25, 2022 Filed Jul 28, 2022 01:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0000899243-22-026922 · doc4.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2032-07-25 F1 · derivative.exercise_date: The option vests as to 50% of the shares on July 25, 2023 and 50% on July 25, 2024. Read SEC document |
| May 20, 2022 Filed May 27, 2022 21:38 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 2,311 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001209191-22-032681 · doc4.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,311 Underlying: Common Stock · 2,311 shares Expires 2032-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 16,714 | $1.72 | $28,748.08 |
DisclosureSEC source: 0000899243-22-017130 · doc4.xml · nonDerivative · entry 2 Panzara Michael A. · CIK 0001679039 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,103 F2 · kind: On May 5, 2022, the reporting person sold 16,714 ordinary shares solely to cover taxes associated with the vesting of the PSUs on May 4, 2022. These sales were made pursuant to a provision in the reporting person's PSU agreement that requires automatic sales of shares to cover tax withholding obligations. The sales are intended to comply with Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.72 to $1.75 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2022 Filed May 6, 2022 23:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017130 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,817 F1 · kind: On March 7, 2019, the reporting person received performance-based restricted share units ("PSUs"), convertible on a one-for-one basis into ordinary shares of the issuer upon vesting. On May 4, 2022, 50% of the PSUs vested upon the issuer's achievement of the PN Chemistry Milestone (as defined in the PSU agreement) following the issuer's recent WVE-004 data release, as certified by the issuer's compensation committee. Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 20:40 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 27,742 | $0.00 Strike: $10.62 | $0.00 |
DisclosureSEC source: 0001209191-22-020266 · doc4.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,742 Underlying: Common Stock · 27,742 shares Expires 2032-03-17 F1 · derivative.exercise_date: One thirty-sixth of the shares subject to the option will vest on April 18, 2022 and one thirty-sixth of the shares subject to the option will vest each month thereafter. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 10,603 | $2.31 | $24,492.93 |
DisclosureSEC source: 0000899243-22-007059 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,817 F1 · kind: On February 16, 2022, the reporting person sold 10,603 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2022. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $2.31 to $2.38 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0000899243-22-000668 · doc4.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2032-01-01 F1 · derivative.exercise_date: The option vests as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:16 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 2,929 | $10.57 | $30,959.53 |
DisclosureSEC source: 0000899243-21-007206 · doc4.xml · nonDerivative · entry 2 Panzara Michael A. · CIK 0001679039 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,420 F2 · kind: On February 16, 2021, the reporting person sold 2,929 ordinary shares solely to cover taxes associated with the vesting of RSUs on February 15, 2021. These sales were made pursuant to a 10b5-1 Trading Plan. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.47 to $10.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:16 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0000899243-21-007206 · doc4.xml · derivative · entry 3 Panzara Michael A. · CIK 0001679039 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2031-02-01 F4 · derivative.exercise_date: The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:16 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007206 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,349 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 01:40 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000899243-20-007277 · doc4.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Ordinary Shares · 36,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022 Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 23:26 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 2,981 | $7.85 | $23,400.85 |
DisclosureSEC source: 0000899243-20-005351 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,349 F1 · kind: On February 18, 2020, the reporting person sold 2,981 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2020. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.84 to $8.17 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 22:11 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 445 | $27.26 | $12,130.70 |
DisclosureSEC source: 0000899243-19-019395 · doc4.xml · nonDerivative · entry 2 Panzara Michael A. · CIK 0001679039 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,330 F1 · kind: Consists of sale of restricted share units (RSUs) effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 22:11 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 2,613 | $26.88 | $70,237.44 |
DisclosureSEC source: 0000899243-19-019395 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,775 F1 · kind: Consists of sale of restricted share units (RSUs) effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $26.25 to $27.21 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 11, 2019 Filed Mar 11, 2019 23:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 7,000 | $48.00 | $336,000.00 |
DisclosureSEC source: 0000899243-19-007113 · doc4.xml · nonDerivative · entry 2 Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,388 F2 · kind: Consists of sale of RSUs effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2018. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 23:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-007113 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,388 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:53 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 1,837 | $36.84 | $67,673.98 |
DisclosureSEC source: 0000899243-19-004466 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,388 F1 · kind: On February 19, 2019, the reporting person sold 1,837 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $36.83 to $37.4713 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:17 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 511 | $52.10 | $26,623.10 |
DisclosureSEC source: 0000899243-18-004951 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,225 F1 · kind: On February 16, 2018, the reporting person sold 511 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2018. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $51.75 to $52.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 00:34 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $21.69 | $0.00 |
DisclosureSEC source: 0000899243-18-004667 · doc4.xml · derivative · entry 3 Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Ordinary Shares · 18,750 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 150,000 ordinary shares, 25% of which became exercisable on July 11, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 00:34 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 18,750 | $50.00 | $937,500.00 |
DisclosureSEC source: 0000899243-18-004667 · doc4.xml · nonDerivative · entry 2 Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,736 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 00:34 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 18,750 | $21.69 | $406,687.50 |
DisclosureSEC source: 0000899243-18-004667 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| January 23, 2018 Filed Jan 26, 2018 01:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002039 · doc4.xml · derivative · entry 2 Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2028-01-23 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25% of the shares quarterly thereafter until February 15, 2022. Read SEC document |
| January 23, 2018 Filed Jan 26, 2018 01:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002039 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,736 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2019, through February 15, 2022. Read SEC document |
| July 12, 2017 Filed Jul 13, 2017 21:09 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 7,414 | $16.67 | $123,619.55 |
DisclosureSEC source: 0000899243-17-018236 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,336 F1 · kind: On July 12, 2017, the reporting person sold 7,414 ordinary shares solely to cover taxes associated with the vesting of restricted share units on July 11, 2017. These sales were made pursuant to a 10b5-1 Trading Plan entered into solely for the purpose described in the prior sentence. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $16.55 to $16.95 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 23:13 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 13,800 | $0.00 Strike: $29.05 | $0.00 |
DisclosureSEC source: 0000899243-17-002144 · doc4.xml · derivative · entry 2 Panzara Michael A. · CIK 0001679039 · Head of Neurology Franchise 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 Underlying: Ordinary Shares · 13,800 shares Expires 2027-01-25 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 15, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 15, 2021. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 23:13 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 6,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-002144 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · Head of Neurology Franchise 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,650 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2018, through February 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.